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Introduction
The establishment of an immortalized continuous cell
line derived from quail cells was undertaken by Baxter
in order to develop a new cell line platform for vaccine
production that is free of genetically modifying
sequences.
Important vaccines and viral vectors are still produced
in embryonated chicken eggs or primary chicken
embryo fibroblasts. However, the substitution of primary
cells by a continuous cell line has several advantages.
Although primary avian tissue for virus replication is
provided by specific pathogen-free (SPF) production
plants, sterility during vaccine production on embryo-
nated eggs is difficult to guarantee, and the constant
risk of contamination necessitates the addition of anti-
biotics. In addition, the supply of embryonated SPF eggs
could be a limiting factor in vaccine production if
increased amounts are demanded by the vaccine manu-
facturers, e. g. in case of a pandemic outbreak.
The same is true for approaches where primary fibro-
blast monolayer cultures are used. Thus, avian cell lines
have become a modern option for vaccine manufactur-
ing and will definitely replace egg and primary fibroblast
technology.
Cell Line Development and Characterization
Here we describe the development of a continuous avian
cell line from quail embryos into serum-free suspension
culture and its manufacturing potential for several dif-
ferent vaccines.
Briefly, embryos of Colinus virginianus virginianus
were disintegrated and trypsinized to obtain a primary
culture that grew adherently in serum-containing
medium. After UV treatment with a specific dose [1],
immortalized cells were expanded and subsequently
adapted to serum-free conditions (QOR2-sf) and growth
in suspension using a chemically defined medium. Sub-
cloning resulted in the isolation of clone QOR2/2E11,
which was selected as the lead clone for development of
vaccine production processes. Then, quality-controlled
cell banks were established (Figure 1). The cell clone
QOR2/2E11 is grown in a chemically defined, animal
component-free medium (Baxter proprietary
formulation).
Quality control (QC) testing was performed at differ-
ent stages during cell line development. Extended char-
acterization according to relevant guidelines (Table 1)
showed that the cells are free of adventitious agents and
F-Pert negative. Tumorigenicity testing performed in
BALB/c nude mice indicated no tumorigenic effect.
Accordingly, the cells fulfill all the critical regulatory
requirements.
Thus, the developed subclone QOR2/2E11 was con-
sidered to be qualified as source material for Good
Manufacturing Practice (GMP) cell bank production. A
pre master cell bank and cell bank derivates were pro-
duced in compliance with the current GMP regulations
and are currently available.
Scalable live virus production in QOR avian cells
For process development purposes, modified vaccinia
Ankara (MVA) virus was used as a model virus. MVA
virus is a highly attenuated strain of vaccinia virus
belonging to the Poxviridae family that was produced by
over 500 passages in chicken embryo fibroblasts. MVA
has lost about 10 % of the vaccinia dsDNA genome and
consequently cannot replicate in primate and human
cells. Its complex genome of circa 200 kb allows the
insertion of large exogenous DNA inserts. Therefore,
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ment of human vaccines against diverse disease targets,
such as malaria and cancer, for which conventional
approaches have so far failed [2].
Using the QOR cell line, high product titers can be
achieved with a broad range of viruses such as wild-type
MVA, recombinant MVA (rMVA) strains, influenza and
flaviviruses. Figure 2 shows the growth of virus in 200
Figure 1 Schematic overview of the cell line history
Table 1 List of guidelines according to which the avian cell line was tested
Organization Number Title
European Directorate for the quality of Medicines &
HealthCare
European
Pharmacopoeia.
(EP) 2.6.16.
Tests for extraneous agents in viral vaccines for human use
EP 5.2.3. Cell substrates for the production of vaccines for human use
The International Conference on Harmonisation of
Technical Requirements for Registration of
Pharmaceuticals for Human Use (ICH)
Q5A (R1)-1999 Viral safety evaluation of biotechnology products derived from
cell lines of human of animal origin
Q5D-1997 Derivation and characterization of cell substrates used for
production of biotechnological/biological products
Q7A-2000 Good manufacturing practice guide for active pharmaceutical
ingredients
Center for Biologics Evaluation & Research (CBER) —— Points to Consider in the Characterization of Cell Lines Used to
Produce Biologicals (1993)
—— Guidance for Industry, Characterization and Qualification of Cell
Substrates and Other Biological Materials Used in the Production
of Viral Vaccines for Infectious Disease Indication (February 2010)
Code of Federal Regulations (CFR) 9CFR113.47 Detection of extraneous agents viruses by fluorescent antibody
technique
21CFR610.18 General biological products standards
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Page 2 of 3ml spinner flask cultures using different rMVA con-
structs. The experiments were performed with a starting
cell density of about 2 x 10
6 cells per ml and a multipli-
city of infection between 1.0 and 0.1. Over the course of
four days post infection (dpi), virus titers of ≥ 1x1 0
9
TCID50 per ml were obtained with every rMVA con-
struct tested. Constant cell performance up to 10L bior-
eactors (laboratory scale), where cell densities ≥ 2x1 0
6
cells per ml were achieved, has been confirmed and
scalability to 100 - 1000L bioreactors is currently under
evaluation.
Furthermore, this avian cell line can serve as a control
cell line with different model viruses in QC tests for
adventitious agents.
Conclusion
A scalable technology for the production of live and
attenuated vaccines based on the qualified avian cell line
QOR2/2E11 has been established. The markedly advan-
tages are:
￿ Stable, continuous avian cell line established without
the introduction of foreign genes
￿ Post production cells are not tumorigenic in animal
model
￿ Suspension growth in low-cost chemically defined
medium
￿ TCID50 titers ≥ 1x1 0
9 for several rMVA constructs
tested
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Figure 2 Growth Kinetics of rMVA viruses on QOR2/2E11
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